Log in with your email address username.


[Correspondence] Trial size, HIV pre-exposure prophylaxis, and breastfeeding

Nicolas Nagot and colleagues (Feb 6, p 566)1 studied HIV-1 prevalence at 50 weeks in 1236 infants who were breastfed in four African countries, and diagnosed 17 HIV-1 infections. Born to HIV-1-infected mothers ineligible for antiretroviral therapy (CD4 count >350 cells per μL), the infants were randomly assigned to extended pre-exposure prophylaxis (for up to 50 weeks) with lopinavir–ritonavir or lamivudine.